Zyrtec

Zyrtec is a consumer-health brand centered on cetirizine, a second-generation antihistamine used to relieve symptoms associated with allergic rhinitis and hives. Its products are intended to address symptoms such as sneezing, runny nose, itchy nose or throat, and itchy or watery eyes; certain formulations are also indicated for temporary relief of itching caused by chronic urticaria. Unlike older first-generation antihistamines, cetirizine was developed and positioned as a less-sedating option, although drowsiness remains a possible side effect for some users. The active ingredient originated from research associated with the Belgian pharmaceutical company UCB. Cetirizine is the active enantiomeric product of hydroxyzine-related antihistamine research and was commercialized internationally under the Zyrtec name and related local brand names. In the United States, Zyrtec was initially available by prescription before becoming one of the major nonprescription allergy brands. The U.S. Food and Drug Administration approved the switch of cetirizine tablets from prescription to over-the-counter status in 2007, expanding consumer access and placing Zyrtec in direct competition with other leading allergy medicines, including loratadine- and fexofenadine-based products. The brand has been marketed through a range of dosage forms and product variants, including standard tablets, chewable tablets, orally disintegrating tablets, and liquid products. Zyrtec-D combines cetirizine with pseudoephedrine for allergy-related nasal congestion, although products containing pseudoephedrine are subject to additional legal and retail controls in the United States. Product availability, labeling, formulations, and regulatory status can differ by country. Zyrtec was historically associated in the United States with Pfizer and later with Johnson & Johnson's McNeil Consumer Healthcare business. Following Johnson & Johnson's separation of its consumer-health operations, the brand became part of Kenvue's consumer-health portfolio. Kenvue markets Zyrtec alongside other self-care brands and sells it through pharmacies, mass retailers, grocery stores, e-commerce channels, and healthcare-related distribution networks. Zyrtec's positioning emphasizes dependable, long-lasting allergy relief and convenience for everyday seasonal or indoor allergies. Its commercial importance comes less from a single patented product than from broad brand recognition, retail distribution, multiple dosage forms, and continued consumer demand for nonprescription allergy treatment. The brand remains active, while its exact ownership and product portfolio may vary across markets.

Zyrtec is the principal consumer brand associated with cetirizine, a second-generation antihistamine developed from research conducted by UCB. Cetirizine was derived from hydroxyzine-related antihistamine research and was designed to provide allergy relief with less central nervous system sedation than many earlier antihistamines. The medicine was commercialized internationally under the Zyrtec name and under related names in some markets. The brand's early commercial history was primarily prescription-based. In the United States, cetirizine was introduced as a prescription allergy treatment before regulatory authorities permitted broader consumer access. The U.S. Food and Drug Administration approved the nonprescription marketing of cetirizine tablets in 2007. This transition significantly changed the brand's role: Zyrtec moved from a medicine primarily selected through a clinician or prescription channel to a mass-market self-care product competing for shelf space and consumer recognition in the highly developed U.S. allergy category. The over-the-counter portfolio expanded beyond a single tablet format. Depending on the market and period, Zyrtec products have included standard tablets, chewable tablets, orally dissolving tablets, liquid formulations, and liquid-gel presentations. The Zyrtec-D line combines cetirizine with pseudoephedrine to address allergy symptoms accompanied by nasal congestion. Because pseudoephedrine is subject to additional controls intended to limit misuse, Zyrtec-D is handled differently from ordinary cetirizine-only products in many U.S. retail settings. In the United States, the brand was associated with Pfizer before its consumer-health commercialization was transferred to Johnson & Johnson's McNeil Consumer Healthcare business. Johnson & Johnson subsequently operated Zyrtec within its consumer-health portfolio, alongside other nonprescription medicines and personal-care brands. In 2023, Johnson & Johnson completed the separation of its consumer-health business under the Kenvue name. Zyrtec is now part of Kenvue's portfolio of self-care brands. Zyrtec's market development has been shaped by the recurring nature of allergic rhinitis and the demand for convenient, nonprescription treatment. Its brand communication has generally emphasized day-long or long-lasting relief, everyday usability, and the ability to treat multiple common allergy symptoms. The brand competes with other major antihistamine franchises based on active ingredient, perceived speed and duration of relief, sedation profile, dosage form, price, and retail availability. Today, Zyrtec remains an active consumer-health brand with broad distribution in the United States and availability in other markets under Zyrtec or locally adapted brand names. Products and indications are not identical worldwide, so consumers are expected to follow the labeling approved in their jurisdiction. The brand's ownership is corporate rather than founder-led, and no single individual is publicly identified as its founder.

• 2023

  Zyrtec enters the Kenvue portfolio

  [2]Kenvue completes separation from Johnson & Johnsonkenvue.com

  Following Johnson & Johnson's separation of its consumer-health operations, Zyrtec became a Kenvue brand.

• 2007

  U.S. over-the-counter approval

  [1]FDA approves over-the-counter Zyrtec Allergy Relieffda.gov

  The FDA approved the switch of cetirizine tablets from prescription to over-the-counter status in the United States.

• Cetirizine developed through UCB antihistamine research

  [4]UCB productsucb.com

  UCB developed cetirizine from hydroxyzine-related antihistamine research and commercialized it internationally under the Zyrtec name and related local names.

A widely distributed, second-generation antihistamine brand positioned around effective, long-lasting, nonprescription relief for seasonal, indoor, and other common allergy symptoms.

• Antihistamine tablets

  Zyrtec Allergy Tablets

  Cetirizine hydrochloride tablets intended for temporary relief of common allergy symptoms, including sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat. They are the core form of the brand's nonprescription allergy offering in the United States.

• Chewable antihistamine

  Zyrtec Allergy Chewables

  Chewable cetirizine products designed for consumers who prefer not to swallow a conventional tablet. Availability, dosage, and approved age ranges depend on the specific product label and market.

• Orally disintegrating antihistamine

  Zyrtec Allergy Dissolve Tabs

  Orally disintegrating cetirizine tablets intended to dissolve in the mouth without requiring a conventional swallow. This format extends the brand's convenience proposition for allergy sufferers.

• Liquid antihistamine

  Zyrtec Allergy Liquid

  Liquid cetirizine formulations intended for users who prefer a measured liquid dosage or who have difficulty taking solid tablets. Exact concentration, directions, and age indications vary by market.

• Antihistamine and decongestant

  Zyrtec-D

  A combination product containing cetirizine and pseudoephedrine. It is intended to provide allergy relief while also addressing nasal congestion. In the United States, pseudoephedrine controls affect how the product is stocked, sold, and purchased.

• 2023

  Transfer into Kenvue's consumer-health portfolioStrategy

  Background

  Johnson & Johnson separated its consumer-health operations into a standalone company focused on self-care, skin health, and essential health products.

  Action taken

  Zyrtec moved into Kenvue's brand portfolio when the separation was completed.

  Aftermath

  The brand continued operating as part of a dedicated publicly traded consumer-health company rather than Johnson & Johnson's former consumer-health division.

  Source

• 2007

  U.S. prescription-to-over-the-counter switchProduct launch

  Background

  Cetirizine had been available by prescription in the United States, while allergy medicines were increasingly moving into consumer self-care channels.

  Action taken

  The FDA approved nonprescription marketing of cetirizine tablets, allowing Zyrtec to be sold directly to consumers subject to over-the-counter labeling requirements.

  Aftermath

  The decision broadened access and made Zyrtec a major participant in the U.S. retail allergy category.

  Source

• 2023

  Johnson & Johnson completes separation of its consumer-health business as Kenvue[2]Kenvue completes separation from Johnson & Johnsonkenvue.com

  M&A

  Zyrtec became part of Kenvue when Johnson & Johnson completed the separation of its consumer-health business. Kenvue's portfolio includes major self-care brands, including Zyrtec in the United States.

• 2007

  FDA approves prescription-to-over-the-counter switch for Zyrtec allergy tablets[1]FDA approves over-the-counter Zyrtec Allergy Relieffda.gov

  Regulation · Product launch

  The U.S. Food and Drug Administration approved the marketing of cetirizine hydrochloride tablets for nonprescription use, enabling the Zyrtec brand to expand from prescription allergy treatment into the U.S. over-the-counter market.

1. 1FDA approves over-the-counter Zyrtec Allergy Relieffda.gov
2. 2Kenvue completes separation from Johnson & Johnsonkenvue.com
3. 3Kenvue products and brandskenvue.com
4. 4UCB productsucb.com